Wedbush Reiterates Outperform Rating for Aprea Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy APRE?
Source: NASDAQ.COM
- Successful Financing: Aprea Therapeutics announced the completion of an oversubscribed private placement financing totaling approximately $30 million, which will provide crucial funding for its clinical trials and product development, enhancing the company's competitiveness in the biopharmaceutical sector.
- Clinical Trial Progress: The company's lead product candidate, APR-1051, is undergoing a Phase 1 clinical trial for patients with advanced solid tumors harboring cancer-associated genetic alterations, with preliminary data showing positive clinical activity, laying the groundwork for future market introduction.
- Dose Escalation Study: The dose-escalation study for APR-1051 is ongoing, with plans to advance to the 300 mg once-daily dose cohort in the second quarter of 2026, which will include patients with uterine serous carcinoma, colorectal cancer, and HPV+ tumors, demonstrating the company's continued commitment to clinical research.
- Market Performance: Aprea Therapeutics' stock has traded between $0.54 and $2.30 over the past year, currently priced at $0.78, reflecting a 5.98% increase, indicating positive market sentiment regarding its clinical advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APRE
Wall Street analysts forecast APRE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.739
Low
4.00
Averages
5.33
High
7.00
Current: 0.739
Low
4.00
Averages
5.33
High
7.00
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wedbush Reiterates Outperform Rating for Aprea Therapeutics
- Successful Financing: Aprea Therapeutics announced the completion of an oversubscribed private placement financing totaling approximately $30 million, which will provide crucial funding for its clinical trials and product development, enhancing the company's competitiveness in the biopharmaceutical sector.
- Clinical Trial Progress: The company's lead product candidate, APR-1051, is undergoing a Phase 1 clinical trial for patients with advanced solid tumors harboring cancer-associated genetic alterations, with preliminary data showing positive clinical activity, laying the groundwork for future market introduction.
- Dose Escalation Study: The dose-escalation study for APR-1051 is ongoing, with plans to advance to the 300 mg once-daily dose cohort in the second quarter of 2026, which will include patients with uterine serous carcinoma, colorectal cancer, and HPV+ tumors, demonstrating the company's continued commitment to clinical research.
- Market Performance: Aprea Therapeutics' stock has traded between $0.54 and $2.30 over the past year, currently priced at $0.78, reflecting a 5.98% increase, indicating positive market sentiment regarding its clinical advancements.
See More
Aprea Therapeutics Secures $30 Million Financing for APR-1051 Development
- Clinical Trial Progress: Aprea Therapeutics reported a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer during its ongoing Phase 1 ACESOT-1051 trial, with a 50% reduction in tumor size at the first imaging assessment and an additional 9.5% reduction at the second assessment, indicating the drug's potential efficacy.
- Enrollment Expansion Plans: The company plans to enroll at least 50 patients with uterine serous carcinoma and other high-need patient groups beyond the existing biomarker-enriched cohorts, addressing significant unmet medical needs, with dose escalation expected to complete by the second quarter of 2027.
- Financing Details: Aprea announced an oversubscribed $30 million private placement led by Soleus Capital, with proceeds intended for general corporate purposes and R&D activities, which is expected to extend the company's cash runway into the first quarter of 2028.
- Stock Performance: APRE shares have traded between $0.54 and $2.30 over the past year, closing at $0.68, down 2.43% on the last trading day, but showing an 8.35% increase in pre-market trading, reflecting positive market sentiment regarding its financing and clinical advancements.
See More
Aprea Therapeutics Reports Q4 2025 Financial Results
- Financial Highlights: Aprea Therapeutics reported a Q4 2025 GAAP EPS of -$0.32, beating expectations by $0.07, indicating a slight improvement in financial performance despite remaining in a loss position.
- Revenue Comparison: The company generated revenue of $3,340 this quarter, a significant drop from $210,000 in the same period last year, reflecting a notable decline in product sales or service demand, which may impact future cash flow.
- Cash Position: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, down from $22.8 million in 2024, indicating pressure on the company's financial management and raising concerns about its future financing capabilities.
- Financing Strategy: Aprea plans to utilize proceeds from a $5.6 million private placement completed in January 2026 to support operations, with expectations that these funds will be sufficient to cover operating and capital expenditure needs into Q1 2027, demonstrating strategic planning for its cash flow.
See More
Aprea Therapeutics Reports Significant Tumor Shrinkage in Early Trial
- Significant Tumor Reduction: Aprea Therapeutics reported a 50% tumor shrinkage in a patient from its early-stage trial of APR-1051, alongside a notable decline in the tumor biomarker CA-125, indicating the drug's potential therapeutic impact and strengthening the company's market outlook.
- Mild Side Effects: The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, suggesting good tolerability of APR-1051, which provides positive safety data for future clinical trials.
- Follow-Up Assessment Plans: The company is eyeing confirmation of the partial responses observed in both patients through subsequent imaging assessments, with further updates expected in Q2 2026, which could positively influence investor confidence.
- Positive Market Reaction: Following the announcement, Aprea's shares surged 15%, with all analysts covering the stock rating it as 'Buy' or higher, and a 12-month average price target of $5.33, representing a potential upside of approximately 788%, reflecting optimistic market sentiment regarding its future performance.
See More
Aprea Therapeutics Reports Positive Cancer Trial Data
- Clinical Trial Progress: Aprea Therapeutics announced a second unconfirmed partial response in a patient with advanced endometrial cancer during its ongoing Phase 1 trial of APR-1051, with a 50% reduction in target lesion measurements, indicating the drug's potential efficacy.
- Significant Biomarker Drop: The CA-125 tumor biomarker levels decreased dramatically from a baseline of 362 U/mL to 47 U/mL during the trial, suggesting promising anti-tumor activity of APR-1051, potentially offering new treatment hope for patients.
- Study Expansion Plans: Aprea plans to expand the study to include more patients with specific genetic alterations to further evaluate the safety and efficacy of APR-1051, with further updates expected in the second quarter of 2026.
- Positive Market Reaction: Aprea Therapeutics shares rose 16.62% to $0.70 at the time of publication, reflecting a positive market response to its clinical data, with analysts generally rating it as a “Buy,” indicating strong investor confidence.
See More
Aprea Therapeutics Reports New Clinical Activity in APR-1051 Trial
- Clinical Trial Progress: Aprea Therapeutics announced new preliminary clinical activity from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, where a patient with advanced endometrial cancer achieved a 50% reduction in target lesions at the 220 mg dose level, indicating the drug's potential in patients with specific genetic mutations.
- Safety and Tolerability: Only Grade 1 adverse events were reported during treatment, demonstrating favorable tolerability of APR-1051 at doses up to 220 mg, which reinforces confidence in its application in genomically defined cancers.
- Stable Disease Cases: The trial also reported five cases of stable disease across multiple tumor types, showcasing APR-1051's potential efficacy in various cancers and further supporting the company's targeted strategy against WEE1.
- Future Outlook: Aprea plans to continue enrolling PPP2R1A-mutated endometrial and HPV-positive head and neck cancer patients in the 220 mg cohort, with an additional update expected in the second quarter of 2026, reflecting the company's positive outlook on future research.
See More
Wedbush Reiterates Outperform Rating for Aprea Therapeutics
- Successful Financing: Aprea Therapeutics announced the completion of an oversubscribed private placement financing totaling approximately $30 million, which will provide crucial funding for its clinical trials and product development, enhancing the company's competitiveness in the biopharmaceutical sector.
- Clinical Trial Progress: The company's lead product candidate, APR-1051, is undergoing a Phase 1 clinical trial for patients with advanced solid tumors harboring cancer-associated genetic alterations, with preliminary data showing positive clinical activity, laying the groundwork for future market introduction.
- Dose Escalation Study: The dose-escalation study for APR-1051 is ongoing, with plans to advance to the 300 mg once-daily dose cohort in the second quarter of 2026, which will include patients with uterine serous carcinoma, colorectal cancer, and HPV+ tumors, demonstrating the company's continued commitment to clinical research.
- Market Performance: Aprea Therapeutics' stock has traded between $0.54 and $2.30 over the past year, currently priced at $0.78, reflecting a 5.98% increase, indicating positive market sentiment regarding its clinical advancements.
See More
Aprea Therapeutics Secures $30 Million Financing for APR-1051 Development
- Clinical Trial Progress: Aprea Therapeutics reported a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer during its ongoing Phase 1 ACESOT-1051 trial, with a 50% reduction in tumor size at the first imaging assessment and an additional 9.5% reduction at the second assessment, indicating the drug's potential efficacy.
- Enrollment Expansion Plans: The company plans to enroll at least 50 patients with uterine serous carcinoma and other high-need patient groups beyond the existing biomarker-enriched cohorts, addressing significant unmet medical needs, with dose escalation expected to complete by the second quarter of 2027.
- Financing Details: Aprea announced an oversubscribed $30 million private placement led by Soleus Capital, with proceeds intended for general corporate purposes and R&D activities, which is expected to extend the company's cash runway into the first quarter of 2028.
- Stock Performance: APRE shares have traded between $0.54 and $2.30 over the past year, closing at $0.68, down 2.43% on the last trading day, but showing an 8.35% increase in pre-market trading, reflecting positive market sentiment regarding its financing and clinical advancements.
See More
Aprea Therapeutics Reports Q4 2025 Financial Results
- Financial Highlights: Aprea Therapeutics reported a Q4 2025 GAAP EPS of -$0.32, beating expectations by $0.07, indicating a slight improvement in financial performance despite remaining in a loss position.
- Revenue Comparison: The company generated revenue of $3,340 this quarter, a significant drop from $210,000 in the same period last year, reflecting a notable decline in product sales or service demand, which may impact future cash flow.
- Cash Position: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, down from $22.8 million in 2024, indicating pressure on the company's financial management and raising concerns about its future financing capabilities.
- Financing Strategy: Aprea plans to utilize proceeds from a $5.6 million private placement completed in January 2026 to support operations, with expectations that these funds will be sufficient to cover operating and capital expenditure needs into Q1 2027, demonstrating strategic planning for its cash flow.
See More
Aprea Therapeutics Reports Significant Tumor Shrinkage in Early Trial
- Significant Tumor Reduction: Aprea Therapeutics reported a 50% tumor shrinkage in a patient from its early-stage trial of APR-1051, alongside a notable decline in the tumor biomarker CA-125, indicating the drug's potential therapeutic impact and strengthening the company's market outlook.
- Mild Side Effects: The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, suggesting good tolerability of APR-1051, which provides positive safety data for future clinical trials.
- Follow-Up Assessment Plans: The company is eyeing confirmation of the partial responses observed in both patients through subsequent imaging assessments, with further updates expected in Q2 2026, which could positively influence investor confidence.
- Positive Market Reaction: Following the announcement, Aprea's shares surged 15%, with all analysts covering the stock rating it as 'Buy' or higher, and a 12-month average price target of $5.33, representing a potential upside of approximately 788%, reflecting optimistic market sentiment regarding its future performance.
See More
Aprea Therapeutics Reports Positive Cancer Trial Data
- Clinical Trial Progress: Aprea Therapeutics announced a second unconfirmed partial response in a patient with advanced endometrial cancer during its ongoing Phase 1 trial of APR-1051, with a 50% reduction in target lesion measurements, indicating the drug's potential efficacy.
- Significant Biomarker Drop: The CA-125 tumor biomarker levels decreased dramatically from a baseline of 362 U/mL to 47 U/mL during the trial, suggesting promising anti-tumor activity of APR-1051, potentially offering new treatment hope for patients.
- Study Expansion Plans: Aprea plans to expand the study to include more patients with specific genetic alterations to further evaluate the safety and efficacy of APR-1051, with further updates expected in the second quarter of 2026.
- Positive Market Reaction: Aprea Therapeutics shares rose 16.62% to $0.70 at the time of publication, reflecting a positive market response to its clinical data, with analysts generally rating it as a “Buy,” indicating strong investor confidence.
See More
Aprea Therapeutics Reports New Clinical Activity in APR-1051 Trial
- Clinical Trial Progress: Aprea Therapeutics announced new preliminary clinical activity from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, where a patient with advanced endometrial cancer achieved a 50% reduction in target lesions at the 220 mg dose level, indicating the drug's potential in patients with specific genetic mutations.
- Safety and Tolerability: Only Grade 1 adverse events were reported during treatment, demonstrating favorable tolerability of APR-1051 at doses up to 220 mg, which reinforces confidence in its application in genomically defined cancers.
- Stable Disease Cases: The trial also reported five cases of stable disease across multiple tumor types, showcasing APR-1051's potential efficacy in various cancers and further supporting the company's targeted strategy against WEE1.
- Future Outlook: Aprea plans to continue enrolling PPP2R1A-mutated endometrial and HPV-positive head and neck cancer patients in the 220 mg cohort, with an additional update expected in the second quarter of 2026, reflecting the company's positive outlook on future research.
See More
